TY - JOUR
T1 - Stimulation of Sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats
AU - Bhuiyan, Md Shenuarin
AU - Fukunaga, Kohji
N1 - Funding Information:
This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (19390150 to K Fukunaga) and the Smoking Research Foundation (to K Fukunaga). The authors state no conflict of interest and have received no payment in preparation of this manuscript.
PY - 2009/11
Y1 - 2009/11
N2 - Objective: Decreased dehydroepiandrosterone (DHEA) levels are associated with endothelial dysfunction and increased cardiovascular mortality in postmenopausal women. We investigated the role of DHEA, also known as sigma-1 receptor (Sig-1R) agonist, in myocardial hypertrophy, cardiac functional recovery and defined mechanisms of cardioprotective action. Methods: Wistar rats subjected to bilateral ovariectomy (OVX) were further treated with abdominal aortic stenosis. DHEA (15 and 30 mg/kg) was administered orally once a day for 14 days starting from 2 weeks after aortic banding. Results: Time course study indicated that left ventricle (LV) weight:body weight (BW) ratio increased time-dependently from 1 to 4 weeks after pressure-overload (PO) with significant inversed regulation of Sig-1R expression. Treatment with the Sig-1R agonist, DHEA, significantly attenuated PO-induced myocardial hypertrophy with increased expression of Sig-1R in the LV. DHEA also attenuated hypertrophy-induced impaired LV end diastolic pressure, LV developed pressure and LV contractility (± dp/dtmax). DHEA treatment significantly restored PO-induced impaired eNOS and Akt activity in the LV. Conclusion: We report, for the first time to our knowledge, the potential role of Sig-1R expression in the heart to attenuate PO-induced hypertrophy in ovariectomized rats. DHEA treatment protects against PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling.
AB - Objective: Decreased dehydroepiandrosterone (DHEA) levels are associated with endothelial dysfunction and increased cardiovascular mortality in postmenopausal women. We investigated the role of DHEA, also known as sigma-1 receptor (Sig-1R) agonist, in myocardial hypertrophy, cardiac functional recovery and defined mechanisms of cardioprotective action. Methods: Wistar rats subjected to bilateral ovariectomy (OVX) were further treated with abdominal aortic stenosis. DHEA (15 and 30 mg/kg) was administered orally once a day for 14 days starting from 2 weeks after aortic banding. Results: Time course study indicated that left ventricle (LV) weight:body weight (BW) ratio increased time-dependently from 1 to 4 weeks after pressure-overload (PO) with significant inversed regulation of Sig-1R expression. Treatment with the Sig-1R agonist, DHEA, significantly attenuated PO-induced myocardial hypertrophy with increased expression of Sig-1R in the LV. DHEA also attenuated hypertrophy-induced impaired LV end diastolic pressure, LV developed pressure and LV contractility (± dp/dtmax). DHEA treatment significantly restored PO-induced impaired eNOS and Akt activity in the LV. Conclusion: We report, for the first time to our knowledge, the potential role of Sig-1R expression in the heart to attenuate PO-induced hypertrophy in ovariectomized rats. DHEA treatment protects against PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling.
KW - Sigma-1 receptor (Sig-1R)
KW - dehydroepiandrosterone (DHEA)
KW - endothelial nitric oxide synthase (eNOS)
KW - myocardial hypertrophy
KW - ovariectomy
KW - protein kinase B (Akt)
UR - http://www.scopus.com/inward/record.url?scp=73449138826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73449138826&partnerID=8YFLogxK
U2 - 10.1517/14728220903264064
DO - 10.1517/14728220903264064
M3 - Article
C2 - 19769544
AN - SCOPUS:73449138826
SN - 1472-8222
VL - 13
SP - 1253
EP - 1265
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 11
ER -